BioLineRx Ltd.
Long
Atualizado

BLRX-BREAKOUT-UPDATE

389
BLRX had a strong rally today and it's just getting started.

In the related idea my price target was $1.34.

Today's high was $1.78

Check out the weekly chart:

snapshot

Photo Finish.

$1.34 was 1.618 extension level from Waves 1 & 2.

Since the price-action broke $1.34 we will have an extended 3rd wave.

I expect a very strong rally tomorrow, I will update in the morning before the open to confirm.

Target is hard to predict since its impossible to know what level extending waves will terminate.

I will keep a close eye on the price-action.

Will update.

-AB






Nota
As expected, a very strong rally today!
Nota
snapshot
Nota
We got a big runway...
Nota
Reminder this is a WEEKLY chart...

Meaning this move is far from over...
Nota
snapshot
Nota
Buckle up!
Nota
snapshot
Nota
Target $2.24 (Sell Half)

Trade Price: 1.049
Nota
snapshot
Nota
snapshot
Nota
Bull Flag
Nota
BLRX will rally again tomorrow.
Nota
snapshot
Nota
BLRX is about to rally again...
Nota
BLRX continued to consolidate today.

Staying the course...
Nota
snapshot
Nota
snapshot
Nota
Near-Term Target: $2.13
Nota
snapshot
Nota
Primary Wave 1 Complete
Nota
snapshot
Nota
03:21 PM EDT, 10/22/2018 (MT Newswires) -- Oppenheimer has kept its outperform rating on BioLineRx (BLRX) with a price target of $3, betting on BL-8040's commercial opportunity as a stem cell mobilizer after top-line data from the COMBAT/KEYNOTE-202 trial of BL-8040 in combination with pembrolizumab in advanced pancreatic cancer showed modest response rate.
"Given the combination's favorable safety profile, BioLineRx and Merck (MRK) are testing a triplet combination including chemotherapy in an effort to increase response rate," analyst Mark Breidenbach said in a note.
"While we believe the triplet combination is worth testing, our valuation of BioLineRx still remains focused on BL-8040's commercial opportunity as a stem cell mobilizer."
Nota
snapshot
Nota
snapshot
Nota
Breakout Imminent
Nota
snapshot

Aviso legal

As informações e publicações não se destinam a ser, e não constituem, conselhos ou recomendações financeiras, de investimento, comerciais ou de outro tipo fornecidos ou endossados pela TradingView. Leia mais nos Termos de Uso.